Related to iPSC-Derived Neurons Shine New Light on Sporadic vs. Familial Alzheimer Disease

• Alzheimer’s Association Puts $4.2M into Initiative to Speed Drug, Biomarker Trials
  
• FDA Clears Avid’s Amyloid Plaque Imaging Agent for Aiding Alzheimer Disease Diagnosis
  
• Stirred Suspension Bioreactors Increase Efficiency of Deriving iPSCs from Fibroblasts
  
• Nuron Gains Preclinical Alzheimer Vaccine from Vitruvian BioMedical
  
• GE Healthcare Partners with Japan’s Clino on Tau Protein PET Agent for Alzheimer Disease
  
• With Acquisition of Bayer Imaging R&D Portfolio, Piramal Continues Shift to Pharma IP
  
• Oligomerix Raises $2M for Tau Protease Inhibitor Alzheimer Disease Program
  
• mAb Therapeutics for Alzheimer Disease Unlikely to Be Fully Successful, According to GEN Poll
  
• Life Technologies, CDI to Commercialize Stem Cell Technologies
  
• Life Technologies Gains Rights to iPS Academia Japan’s Patents
  
• Genentech Taps AC Immune in Second Alzheimer Drug Development Deal
  
• VTT Joins with GE Healthcare to Validate Alzheimer Disease Biomarker
  
• Muscular Dystrophy Treated Using Genetically Corrected iPSC-Derived Mesoangioblasts
  
• AstraZeneca Acquires Neurodegenerative Disease Assets and Establishes Research Consortium
  
• Pfizer-Janssen Alzheimer's Treatment Misses Phase III Endpoints
  
• Alzheimer's Disease Antibody Bombs
  
• Blood Test Detects Alzheimer’s and Early Cognitive Decline
  
• Fragment-Based Drug Discovery for Alzheimer’s
  
• Firms Offer iPSC Cardiac Toxicity Screening
  
• Cord Blood Cells Efficiently Reprogrammed into hiPSCs